Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of FRSW117 in previously treated severe hemophilia A adolescents and adults
CTR20233517Phase 3Completed
- Sponsor
- Suns Biopharma
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of pegylated recombinant human coagulation factor VIII-Fc fusion protein in hemophilia A, sponsored by Suns Biopharma. Started Nov 2023; status: completed.
02
Drugs
pegylated recombinant human coagulation factor VIII-Fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20233517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233517.